VYNE Therapeutics Inc. amended its merger agreement with Yarrow Bioscience on January 30, 2026, allowing for pre-funded warrants to be issued to certain Yarrow shareholders if their shareholdings exceed a specified limit. This filing is significant for investors as it impacts the ownership structure post-merger.